The European Commission Awards a proposal from Biohope with The Seal of Excellence Certificate.
The Seal of Excellence Certificate is a quality label awarded by the Commission to projects by companies which have been assessed in a call for proposals under a Union instrument and comply with its qual [...]
Dra. Isabel Portero included in the report “Referent Women in Innovative Entrepreneurship in Spain”
The report, based on surveys, has been done and coordinated by the High Commissioner of Entrepreneurship in Spain, which is an organism of the Government Presidency. This recognition reflects the role Dr [...]
Immunobiogram® has been granted a US patent by USPTO
Biohope´s lead product, the Immunobiogram®, has been granted a US patent by the United States Patent and Trademark Office. This new patent complements and consolidates Biohope´s intellectual property pr [...]
Podcast Woman Business. Isabel Portero, CEO de BIOHOPE
“La audacia no hay que asociarla a un perfil de joven promesa o a una franja de edad” "En este episodio hablamos con Isabel Portero, una médica de profesión, especialista en Medicina Interna, que trabajab [...]
Biohope Finalist and Honorable Mention at the Innovation Challenge “Thriving with Transplantation”
Biohope had an outstanding result at the 2021 Lyfebulb-CSL Behring Innovation Challenge recently celebrated, by becoming a finalist and receiving an honorable mention form the jury. The goal of the Innova [...]
Biohope Partners with Palex Medical to Commercialize the Product Immunobiogram®- Renal Transplant in Spain.
Madrid, March 2021 – Biohope, a Spanish biotechnological company that investigates, develops and commercializes unique medical solutions in the field of chronic inflammation and autoimmune diseases, has s [...]
Recent Publication by Biohope in Frontiers in Immunology.
The prestigious international journal, “Frontiers in Immunology”, has recently published a paper about the Immunobiogram technology, called “The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment [...]
Biohope reached the CE Mark for the IMMUNOBIOGRAM®
In October, Biohope reached the CE Mark for the IMMUNOBIOGRAM®, a first in class IVD test for the in-vitro measurement of metabolic activity of patient’s immune cells as response to individual immunosuppr [...]